

Table 3. Conservation of validated miRNA binding sites in cancer-related target genes.

| wt genes | corresponding pseudogene(s) | validated miRNA families | conservation of the binding site between wt and pseudo |
|---------------|-----------------------------|--------------------------------|--|
| <i>CCND3</i> | <i>CCND3P</i> | <i>miR-16</i> ¹ | no* |
| <i>CDK4</i> | <i>CDK4PS</i> | <i>miR-34</i> ² | yes |
| <i>DNMT3A</i> | <i>DNMT3AP1</i> | <i>miR-29</i> ³ | no |
| | | <i>miR-143</i> ⁴ | no |
| <i>E2F3</i> | <i>E2F3P1</i> | <i>miR-17</i> ⁵ | yes |
| | | <i>miR-34</i> ⁶ | no |
| <i>c-MYC</i> | <i>MYCL3</i> | <i>let-7</i> ⁷ | no* |
| | | <i>miR-145</i> ⁸ | no* |
| <i>OCT4</i> | <i>OCT4-pg1,2,3,4,5,6</i> | <i>miR-145</i> ⁹ | yes |
| <i>KRAS</i> | <i>KRAS1P</i> | <i>let-7</i> ¹⁰ | yes |
| | | <i>miR-143</i> ¹¹ | yes |
| <i>PTEN</i> | <i>PTENP1</i> | <i>miR-17</i> ¹² | yes |
| | | <i>miR-19</i> ^{13,14} | yes |
| | | <i>miR-21</i> ¹⁵ | yes |
| | | <i>miR-26</i> ¹⁶ | yes |
| | | <i>miR-214</i> ¹⁷ | yes |
| | | <i>miR-216</i> ¹⁸ | no |
| <i>FOXO3</i> | <i>FOXO3B</i> | <i>miR-217</i> ¹⁸ | no |
| | | <i>miR-182</i> ¹⁹ | yes |

A list of miRNA families with a well recognized oncogenic or oncosuppressor role was obtained merging the most recent reviews about microRNAs and cancer²⁰⁻²⁴.

The validated targets of these miRNAs that have at least 1 pseudogene (<http://www.genecards.org>) are listed above. The conservation of the binding sites of the validated miRNAs in the pseudogene(s) is also reported. The asterisk indicates those wt/pseudogene pairs that show an overall low sequence conservation (<60%).

The conservation of *miR-17*, *19*, *21*, *26* and *214* binding sites in *PTENP1* has been discussed elsewhere (**Fig. 1**). Analogously, the conservation of *miR-145* binding sites in *OCT4* pseudogenes has been described in **Table 2**.

References 1-24

- 1 Liu, Q. *et al.*, miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. *Nucleic Acids Res* 36 (16), 5391-5404 (2008).
- 2 He, L., He, X., Lowe, S.W., & Hannon, G.J., microRNAs join the p53 network--another piece in the tumour-suppression puzzle. *Nat Rev Cancer* 7 (11), 819-822 (2007).
- 3 Fabbri, M. *et al.*, MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proc Natl Acad Sci U S A* 104 (40), 15805-15810 (2007).
- 4 Ng, E.K. *et al.*, MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. *Br J Cancer* 101 (4), 699-706 (2009).
- 5 Sylvestre, Y. *et al.*, An E2F/miR-20a auto-regulatory feed-back loop. *J Biol Chem* (2006).
- 6 Welch, C., Chen, Y., & Stallings, R.L., MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. *Oncogene* 26 (34), 5017-5022 (2007).
- 7 Sampson, V.B. *et al.*, MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. *Cancer Res* 67 (20), 9762-9770 (2007).
- 8 Sachdeva, M. *et al.*, p53 represses c-Myc through induction of the tumor suppressor miR-145. *Proc Natl Acad Sci U S A* 106 (9), 3207-3212 (2009).
- 9 Xu, N., Papagiannakopoulos, T., Pan, G., Thomson, J.A., & Kosik, K.S., MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. *Cell* 137 (4), 647-658 (2009).
- 10 Johnson, S.M. *et al.*, RAS is regulated by the let-7 microRNA family. *Cell* 120 (5), 635-647 (2005).
- 11 Chen, X. *et al.*, Role of miR-143 targeting KRAS in colorectal tumorigenesis. *Oncogene* 28 (10), 1385-1392 (2009).
- 12 Xiao, C. *et al.*, Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. *Nat Immunol* 9 (4), 405-414 (2008).
- 13 Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., & Burge, C.B., Prediction of mammalian microRNA targets. *Cell* 115 (7), 787-798 (2003).
- 14 Takakura, S. *et al.*, Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. *Cancer Sci* 99 (6), 1147-1154 (2008).
- 15 Meng, F. *et al.*, Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. *Gastroenterology* 130 (7), 2113-2129 (2006).
- 16 Huse, J.T. *et al.*, The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. *Genes Dev* 23 (11), 1327-1337 (2009).
- 17 Yang, H. *et al.*, MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. *Cancer Res* 68 (2), 425-433 (2008).
- 18 Kato, M. *et al.*, TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. *Nat Cell Biol* (2009).
- 19 Segura, M.F. *et al.*, Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. *Proc Natl Acad Sci U S A* 106 (6), 1814-1819 (2009).

- ²⁰ Ventura, A. & Jacks, T., MicroRNAs and cancer: short RNAs go a long way. *Cell* 136 (4), 586-591 (2009).
- ²¹ Garzon, R., Calin, G.A., & Croce, C.M., MicroRNAs in Cancer. *Annu Rev Med* 60, 167-179 (2009).
- ²² Visone, R. & Croce, C.M., MiRNAs and cancer. *Am J Pathol* 174 (4), 1131-1138 (2009).
- ²³ Medina, P.P. & Slack, F.J., microRNAs and cancer: an overview. *Cell Cycle* 7 (16), 2485-2492 (2008).
- ²⁴ Ma, L. & Weinberg, R.A., Micromanagers of malignancy: role of microRNAs in regulating metastasis. *Trends Genet* 24 (9), 448-456 (2008).